Overview

Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia

Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca